Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05774665 · ClinicalTrials.gov registry record · Phase 2
Specialized Pro-resolving Lipid Mediators and Treatment Resistant Depression
A Phase 2 study of Overweight and Inflammation, sponsored by Massachusetts General Hospital.
- Active
- Registry status
- Phase 2
- Development phase
- 80
- Enrollment target
- 3
- Study locations
NCT05774665: Active Phase 2 study of Overweight and Inflammation, sponsored by Massachusetts General Hospital.
NCT05774665 is a Phase 2 study of Overweight and Inflammation that is active but no longer recruiting, run by Massachusetts General Hospital. The registered enrollment target is 80 participants, below the 1,323-participant average among 197 other Overweight trials with a reported enrollment target (94% lower). The trial reports 3 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05774665, a Phase 2 study of Overweight and Inflammation, is active but no longer recruiting, sponsored by Massachusetts General Hospital.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 80 participants
- Enrollment target
- 3
- Study locations
Study Summary
The goal of this clinical trial is to determine the impact of omega-3 fatty acids on the production of anti-inflammatory effects and clinical improvement in people with depression who have not responded well to standard antidepressant treatment. The main questions it seeks to answer are: 1. Do omega-3 fatty acids added to ineffective antidepressant treatment increase production of compounds that reduce inflammation? 2. Is the increase in these anti-inflammatory compounds associated with a stronger antidepressant effect? Participants taking antidepressants that have not worked completely will be assigned at random for a 12-week period to one of the following: 1. an omega-3 preparation 2. an inactive placebo During the course of the study, blood tests will be obtained for compounds associated with inflammation, and questionnaires to measure clinical improvement in depressive symptoms will be administered.
Primary Outcome
Evaluate change in plasma 18-HEPE (18-hydroxy eicosapentaeoic acid) levels associated with 12 weeks of 4 g/day EPA-enriched n-3 treatment vs placebo.
Conditions Studied
Interventions
- OTHER Placebo
- DRUG Omega 3
Study Locations (3)
Georgia
- Emory University School of Medicine - Atlanta
Massachusetts
- Depression Clinical and Research Program at Massachusetts General Hospital - Boston
Utah
- University of Utah - Salt Lake City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 80 participants |
| Start Date | 2025-01-30 |
| Est. Completion | 2026-03-31 |
| Phase | Phase 2 |
What the registry record for NCT05774665 still lists
NCT05774665 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 80 participants, a relatively small participant target, below the 1,323-participant average among 197 other Overweight trials with a reported enrollment target (94% lower).
The record links to 3 conditions, with Overweight appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT05774665 reports a single indexed study location in Georgia, Massachusetts, Utah.
Frequently Asked Questions
What is clinical trial NCT05774665 about?
NCT05774665 is a clinical study titled "Specialized Pro-resolving Lipid Mediators and Treatment Resistant Depression". The goal of this clinical trial is to determine the impact of omega-3 fatty acids on the production of anti-inflammatory effects and clinical improvement in people with depression who have not responded well to standard antidepressant treatment. The main questions it seeks to answer are: 1. Do omeg...
What is the current status of trial NCT05774665?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 80 participants. The study started on 2025-01-30. Estimated completion is 2026-03-31.
What conditions does trial NCT05774665 study?
This clinical trial studies the following conditions: Overweight, Inflammation, Treatment-Resistant Depression.
What interventions are being tested in trial NCT05774665?
The interventions under investigation include: Placebo (OTHER), Omega 3 (DRUG).
Who is sponsoring clinical trial NCT05774665?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05774665 being conducted?
This trial has 3 study locations across Georgia, Massachusetts, Utah. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Overweight
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05774665's enrollment target sits among peer trials
80 120th of 197 higher than 76 of 197 other Overweight trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Overweight trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Tirzepatide: Reversal of Lipotoxicity and Adipose Tissue Dysfunction in Humans With Overweight/Obesity
RECRUITING · Phase 2
-
A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight
RECRUITING · Phase 2
-
A Research Study on How Well Different Doses of the Medicine NNC0662-0419 Help People Living With Overweight or Obesity
RECRUITING · Phase 2
-
Taxi ROADmAP (Realizing Optimization Around Diet And Physical Activity)
RECRUITING · Phase 2
-
A Research Study on How Well Different Doses of the Medicine UBT251 Help People Living With Overweight or Obesity
RECRUITING · Phase 2
-
Semaglutide for Post-Smoking Cessation Weight Management
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01243931 · 80 participants · NA
Optical Coherence Tomography Guided Transepithelial Phototherapeutic Keratectomy
- NCT01659203 · 80 participants · Phase 1
Proton or Photon RT for Retroperitoneal Sarcomas
- NCT01803451 · 80 participants · Early Phase 1
Glucagon-like Peptide 1, Glucose Metabolism and Gastric Bypass
- NCT01964859 · 80 participants · Phase 2
Feasibility Study for Fibroblast Autologous Skin Grafts
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI